Exploring the role of lipoprotein(a) in cardiovascular diseases and diabetes in Chinese population

Hussain, Zubair; Liu, Hongcai; Iqbal, Junaid; Zhou, Haoming

doi:10.1016/j.ijbiomac.2023.123586

Cited by 4 publications

(4 citation statements)

References 134 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We have not found studies in the literature confirming or refuting these observations, hence the need to conduct longitudinal and cross-sectional studies that could elucidate this enigma. Racial variability has especially been noted with regard to plasma Lp(a) concentrations, with individuals of African ancestry having on average higher concentrations than individuals of European or Asian ancestry [7,22,23]. These important remarks regarding the average plasma values of Lp(a) in black individuals deserve to be taken into consideration with the carrying out in Senegal of independent studies with the aim of establishing the reference values of Lp(a) and to be able to correctly manage subjects with hyperlipoproteinemia (a).…”

Section: Discussionmentioning

confidence: 99%

Assessment of Serum Lipoprotein(a) Status in Type 2 Diabetes Mellitus

Sambou,

Diouf,

Coly

et al. 2024

IJBcRR

View full text Add to dashboard Cite

Introduction: Lipoprotein (a) is made up of an atherogenic LDL lipoparticle and a potentially thrombogenic apoprotein a and is therefore responsible for cardiovascular disease. The objective of this study is to evaluate serum lipoprotein (a) status and to investigate the correlation of elevated serum lipoprotein (a) levels with other cardiovascular risk factors in type 2 diabetics. Materials and Methods: This is a case-control study involving 82 patients, 37 type 2 diabetic patients and 45 non-diabetic control subjects. Sociodemographic data were collected and each patient underwent routine lipid assessment and lipoprotein (a) testing. Results: The prevalence of hyperlipoproteinemia (a) is 17.8% in control subjects and 29.7% in type 2 diabetics. HDL cholesterolemia is significantly higher in controls than in type 2 diabetics (p =0.028) while LDL cholesterol and serum lipoprotein (a) levels are higher in type 2 diabetics than in controls with a statistically significant difference (p=0.025 and p=0.026 respectively). The mean lipoprotein (a) values of 0.36±0.34 g/l in women are higher than those of male subjects which are 0.28±0.20 g/l (p=0.171). Mean serum lipoprotein (a) levels of 0.39±0.32 g/l in type 2 diabetics are significantly higher than those of controls which are 0.25±0.21 g/l (p= 0.026). Plasma concentrations of lipoprotein (a) vary with age and appear to be increased beyond the age of 45. There is no correlation between lipoprotein (a) and other cardiovascular risk factors. Conclusion: Hyperlipoproteinemia (a) is common in type 2 diabetics and women have the highest plasma levels. Serum lipoprotein (a) concentrations are not correlated with other cardiovascular risk factors and therefore constitute an independent risk factor.

show abstract

Section: Discussionmentioning

confidence: 99%

Assessment of Serum Lipoprotein(a) Status in Type 2 Diabetes Mellitus

Sambou,

Diouf,

Coly

et al. 2024

IJBcRR

View full text Add to dashboard Cite

show abstract

“…It was estimated that the genetic variations at LPA locus explained 30%-40% of the variance in lipoprotein (a) [Lp(a)] plasma concentration. 34 And increased Lp(a) levels associates to a higher risk of CHD and ST in people with or without diabetes. On the contrary, for the new onset of T2D, low levels of Lp(a) were demonstrated as a risk factor.…”

Section: Discussionmentioning

confidence: 99%

“…A potential mechanism is that both the excess and reduced Lp(a) are led by autoimmune response, a common origin of CMDs. 34,35 The 9p21 locus has been identified as the strongest genetic signal for CHD in European individuals since 2007. The genetic risk of T2D shows an approximate result.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Genome‐wide association study of cardiometabolic multimorbidity in the UK Biobank

Zhao,

Ma,

Cheng

et al. 2024

Clinical Genetics

View full text Add to dashboard Cite

Considering the high prevalence and poor prognosis of cardiometabolic multimorbidity (CMM), identifying causal factors and actively implementing preventive measures is crucial. However, Mendelian randomization (MR), a key method for identifying the causal factors of CMM, requires knowledge of the effects of SNPs on CMM, which remain unknown. We first analyzed the genetic overlap of single cardiometabolic diseases (CMDs) using the latest genome‐wide association study (GWAS) for evidential support and comparison. We observed strong positive genetic correlations and shared loci among all CMDs. Further, GWAS and post‐GWAS analyses of CMM were performed in 407 949 European ancestry individuals from the UK Biobank. Eleven loci and 12 lead SNPs were identified. By comparison, we found these SNPs were a subset of SNPs associated with CMDs, including both shared and non‐shared SNPs. Then, the polygenic risk score model predicted the risk of CMM (C‐index = 0.62) and we identified candidate genes related to lipid metabolism and immune function. Finally, as an example, two‐sample MR analysis based on the GWAS revealed potential causal effects of total cholesterol, serum urate, body mass index, and smoking on CMM. These results provide a basis for future MR research and inspire future studies on the mechanism and prevention of CMM.

show abstract

Lipoprotein(a): Are we ready for large-scale clinical trials?

Zheng,

Fang,

et al. 2024

International Journal of Cardiology

View full text Add to dashboard Cite

Exploring the role of lipoprotein(a) in cardiovascular diseases and diabetes in Chinese population

Cited by 4 publications

References 134 publications

Assessment of Serum Lipoprotein(a) Status in Type 2 Diabetes Mellitus

Assessment of Serum Lipoprotein(a) Status in Type 2 Diabetes Mellitus

Genome‐wide association study of cardiometabolic multimorbidity in the UK Biobank

Lipoprotein(a): Are we ready for large-scale clinical trials?

Contact Info

Product

Resources

About